Ligand Pharmaceuticals LGND Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's debt issuance cost amortization?
- Ligand Pharmaceuticals (LGND) reported debt issuance cost amortization of $803K in Q1 2026.
- How has Ligand Pharmaceuticals's debt issuance cost amortization changed year-over-year?
- Ligand Pharmaceuticals's debt issuance cost amortization increased by 490.4% year-over-year, from $136K to $803K.
- What is the long-term trend for Ligand Pharmaceuticals's debt issuance cost amortization?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's debt issuance cost amortization has grown at a -47.4% compound annual growth rate (CAGR), from $16.69M to $1.27M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).